58
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Antiviral Activity of Reagents in Mouth Rinses against SARS-CoV-2

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The oral cavity, an essential part of the upper aerodigestive tract, is believed to play an important role in the pathogenicity and transmission of SARS-CoV-2. The identification of targeted antiviral mouth rinses to reduce salivary viral load would contribute to reducing the COVID-19 pandemic. While awaiting the results of significant clinical studies, which to date do not exist, the commercial availability of mouth rinses leads us to search among them for reagents that would have specific antiviral properties with respect to SARS-CoV-2. The challenges facing this target were examined for 7 reagents found in commercially available mouth rinses and listed on the ClinicalTrials.gov website: povidone-iodine, chlorhexidine, hydrogen peroxide, cyclodextrin, Citrox, cetylpyridinium chloride, and essential oils. Because SARS-CoV-2 is an enveloped virus, many reagents target the outer lipid membrane. Moreover, some of them can act on the capsid by denaturing proteins. Until now, there has been no scientific evidence to recommend mouth rinses with an anti–SARS-CoV-2 effect to control the viral load in the oral cavity. This critical review indicates that current knowledge of these reagents would likely improve trends in salivary viral load status. This finding is a strong sign to encourage clinical research for which quality protocols are already available in the literature.

          Related collections

          Most cited references55

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Cell entry mechanisms of SARS-CoV-2

          Significance A key to curbing SARS-CoV-2 is to understand how it enters cells. SARS-CoV-2 and SARS-CoV both use human ACE2 as entry receptor and human proteases as entry activators. Using biochemical and pseudovirus entry assays and SARS-CoV as a comparison, we have identified key cell entry mechanisms of SARS-CoV-2 that potentially contribute to the immune evasion, cell infectivity, and wide spread of the virus. This study also clarifies conflicting reports from recent studies on cell entry of SARS-CoV-2. Finally, by highlighting the potency and the evasiveness of SARS-CoV-2, the study provides insight into intervention strategies that target its cell entry mechanisms.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

            SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further in vitro and in vivo studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Consistent Detection of 2019 Novel Coronavirus in Saliva

              Abstract The 2019 novel coronavirus (2019-nCoV) was detected in the self-collected saliva of 91.7% (11/12) of patients. Serial saliva viral load monitoring generally showed a declining trend. Live virus was detected in saliva by viral culture. Saliva is a promising noninvasive specimen for diagnosis, monitoring, and infection control in patients with 2019-nCoV infection.
                Bookmark

                Author and article information

                Journal
                J Dent Res
                J Dent Res
                JDR
                spjdr
                Journal of Dental Research
                SAGE Publications (Sage CA: Los Angeles, CA )
                0022-0345
                1544-0591
                22 October 2020
                : 0022034520967933
                Affiliations
                [1 ]University Claude Bernard Lyon 1, Laboratory “Systemic Health Care,” University of Lyon, Lyon, France
                [2 ]Faculty of Dentistry, Estacio de Sá University, Rio de Janeiro, Brazil
                [3 ]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
                [4 ]Department of Restorative, Preventive and Pediatric Dentistry, Faculty of Dental Medicine, University of Bern, Bern, Switzerland
                [5 ]THEnet, Training for Health Equity Network, New York, NY, USA
                [6 ]RESCUe-RESUVal Network, Lucien Hussel Hospital, Vienne, France
                [7 ]Emilie Roux Hospital Center, Le Puy-en-Velay, France
                [8 ]Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, Rome, Italy
                Author notes
                [*]Florence Carrouel, University Claude Bernard Lyon 1, Laboratory “Systemic Health Care,” University of Lyon, EA4129, 11 rue Guillaume Paradin, Lyon, 69008, France Email: florence.carrouel@ 123456univ-lyon1.fr
                Author information
                https://orcid.org/0000-0002-6823-1636
                Article
                10.1177_0022034520967933
                10.1177/0022034520967933
                7582358
                33089717
                d4f9075b-4711-4e8f-8d22-6a64224ac1fd
                © International & American Associations for Dental Research 2020

                This article is distributed under the terms of the Creative Commons Attribution 4.0 License ( https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page ( https://us.sagepub.com/en-us/nam/open-access-at-sage).

                History
                Categories
                Critical Reviews in Oral Biology & Medicine
                Custom metadata
                corrected-proof
                ts1

                covid-19,mouthwashes,saliva,oral,viral load,clinical trial
                covid-19, mouthwashes, saliva, oral, viral load, clinical trial

                Comments

                Comment on this article